Does Rallies show Form 4 insider transactions for ALLO?

Yes. Rallies tracks ALLO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ALLO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ALLO. It does not provide personalized investment advice.

ALLO (Allogene Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Allogene Therapeutics, Inc. Common Stock (ALLO) is a publicly traded Healthcare sector company. As of May 21, 2026, ALLO trades at $1.92 with a market cap of $669.60M and a P/E ratio of -2.17. ALLO moved +0.53% today. Year to date, ALLO is +40.74%; over the trailing twelve months it is +63.79%. Its 52-week range spans $0.86 to $4.46. Analyst consensus is strong buy with an average price target of $8.71. Rallies surfaces ALLO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ALLO stock inside the company?

Recent ALLO insider activity includes Yoshiyama Annie sold 9.59K, Beneski Benjamin Machinas sold 2.87K, Beneski Benjamin Machinas sold 4.83K, Chang David D sold 47.76K, and Beneski Benjamin Machinas sold 7.13K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ALLO Key Metrics

Key financial metrics for ALLO
Metric	Value
Price	$1.92
Market Cap	$669.60M
P/E Ratio	-2.17
EPS	$-0.87
Dividend Yield	0.00%
52-Week High	$4.46
52-Week Low	$0.86
Volume	522
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-190.89M
Gross Margin	0.00%

Recent ALLO Insider Trades

Yoshiyama Annie sold 9.59K (~$22.14K) on Apr 21, 2026.
Beneski Benjamin Machinas sold 2.87K (~$7.17K) on Mar 31, 2026.
Beneski Benjamin Machinas sold 4.83K (~$11.94K) on Mar 16, 2026.
Chang David D sold 47.76K (~$117.97K) on Mar 16, 2026.
Beneski Benjamin Machinas sold 7.13K (~$18.54K) on Mar 2, 2026.

Latest ALLO News

Allogene Therapeutics Q1 Runway Extended, ALLO-501 Posts 65% Response Rate — May 14, 2026
58.3% MRD Clearance in Phase 2 ALPHA3 Trial Bolsters Allogene’s 2029 Cash Runway — May 13, 2026
Allogene Showcases BCMA/CD70 Dual AlloCAR T Data and Dagger® Autoimmune Platform at AACR 2026 — Apr 20, 2026
Allogene Raises $200.4M via 100.2M Share Public Offering — Apr 16, 2026
Allogene’s ALLO-329 Dual CAR T Shows Lupus Model Efficacy, Phase 1 Data June 2026 — Apr 15, 2026

ALLO Analyst Consensus

14 analysts cover ALLO: 0 strong buy, 12 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.71.

Common questions about ALLO

Who is trading ALLO stock inside the company?: Recent ALLO insider activity includes Yoshiyama Annie sold 9.59K, Beneski Benjamin Machinas sold 2.87K, Beneski Benjamin Machinas sold 4.83K, Chang David D sold 47.76K, and Beneski Benjamin Machinas sold 7.13K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ALLO?: Yes. Rallies tracks ALLO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ALLO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ALLO. It does not provide personalized investment advice.